

REF



SYSTEM

08860181119

08860181500

100

cobas e 801

English

System information

Short name	ACN (application code number)
PAPPA	10089

Please note

The measured PAPP-A value of a patient's sample can vary depending on the testing procedure used. The laboratory finding must therefore always contain a statement on the PAPP-A assay method used. PAPP-A values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. If there is a change in the PAPP-A assay procedure used while monitoring therapy, then the PAPP-A values obtained upon changing over to the new procedure must be confirmed by parallel measurements with both methods.

Intended use

Immunoassay for the in vitro quantitative determination of pregnancy-associated plasma protein A in human serum.

This assay is intended for the use as one component in combination with other parameters to evaluate the risk of trisomy 21 (Down syndrome) during the first trimester of pregnancy. Further testing is required for diagnosis of chromosomal aberrations.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the **cobas e 801** immunoassay analyzer.

Note: Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the licensed 11-digit Catalogue Number: 08860181190 for the Elecsys PAPP-A assay. The last 3 digits -190 have been replaced by -119 for logistic purposes.

Summary

Human pregnancy-associated plasma protein A (PAPP-A) is a large glycoprotein composed by 2 subunits with a total molecular weight of 200 kDa. PAPP-A belongs to the metzincin superfamily of zinc peptidases and was first isolated from the serum of pregnant women, where its concentration increases steadily until term. PAPP-A is produced by the trophoblast and secreted into the maternal serum, where it mainly circulates as a heterotetrameric 2:2 complex, together with 2 subunits of the proform of eosinophil major basic protein (proMBP).^{1,2,3}

PAPP-A, in combination with free β hCG and the sonographic determination of nuchal translucency (NT), identifies women at increased risk of carrying a fetus affected with Down syndrome during the first trimester (week 8-14) of pregnancy.^{4,5,6} Using this marker combination, detection rates of up to 70 % (serum markers only) and 90 % (combined with NT) have been described at a false positive rate of 5 %.^{5,7,8,9}

When the sonographic examination also includes the presence of the nasal bone, the detection rate is found to reach 97 %.¹⁰ Based on the maternal age, the risk for having a Down syndrome pregnancy can be calculated using a specific algorithm.^{5,11,12} Based on the risk assessment thus obtained, Non-Invasive Prenatal Testing (NIPT) on cell-free fetal DNA or invasive diagnosis may be indicated.^{13,14,15,16} Women found to have increased risk of aneuploidy with 1st trimester screening should be offered genetic counselling and the option of Chorionic Villus Sampling (CVS) or amniocentesis.¹⁷

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 9 μ L of sample, a biotinylated monoclonal PAPP-A-specific antibody and a monoclonal PAPP-A-specific antibody labeled with a ruthenium complex^{a)} react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas link**.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The **cobas e** pack is labeled as PAPP-A.

- M Streptavidin-coated microparticles, 1 bottle, 5.8 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-PAPP-A-Ab~biotin, 1 bottle, 9.9 mL:
Biotinylated monoclonal anti-PAPP-A antibody (mouse) 2.0 mg/L;
TRIS buffer 50 mmol/L, pH 7.0; preservative.
- R2 Anti-PAPP-A-Ab~Ru(bpy)₃²⁺, 1 bottle, 10.3 mL:
Monoclonal anti-PAPP-A antibody (mouse) labeled with ruthenium complex 1.0 mg/L; phosphate buffer 50 mmol/L, pH 7.4; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:

2-methyl-2H-isothiazol-3-one hydrochloride

EUH 208 May produce an allergic reaction.

Product safety labeling follows EU GHS guidance.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is available via the **cobas link**.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
on the cobas e 801 analyzer	16 weeks

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Do not use plasma.

Stable for 25 hours at 20-25 °C, 8 days at 2-8 °C, 12 months at -20 °C (\pm 5 °C). The samples may be frozen 3 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement. Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See “Reagents – working solutions” section for reagents.

Materials required (but not provided)

- [REF] 04854101200, PAPP-A CalSet, for 4 x 1.0 mL
- [REF] 04899881200, PreciControl Maternal Care, for 6 x 2.0 mL
- [REF] 07299001190, Diluent Universal, 45.2 mL sample diluent
- General laboratory equipment
- **cobas e** 801 analyzer

For risk calculation of trisomy 21:

- [REF] 08860297190, Elecsys free β hCG, 100 tests
- [REF] 04854080200, free β hCG CalSet, for 4 x 1.0 mL
- A suitable software

Additional materials for the **cobas e** 801 analyzer:

- [REF] 06908799190, ProCell II M, 2 x 2 L system solution
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 07485409001, Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF] 06908853190, PreClean II M, 2 x 2 L wash solution
- [REF] 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- [REF] 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF] 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator’s manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

Calibration

Traceability: This method has been standardized against a commercially available PAPP-A test, which in turn was standardized against the WHO standard preparation IRP 78/610.

The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Maternal Care.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory’s individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in mIU/L, IU/L or mIU/mL).

Conversion factors: $mIU/mL \times 1000 = mIU/L$
 $mIU/mL \times 1 = IU/L$
 $IU/L \times 1000 = mIU/L$

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

Compound	Concentration tested
Bilirubin	$\leq 205 \mu\text{mol/L}$ or $\leq 12 \text{ mg/dL}$
Hemoglobin	$\leq 0.621 \text{ mmol/L}$ or $\leq 1000 \text{ mg/dL}$
Intralipid	$\leq 1500 \text{ mg/dL}$
Biotin	$\leq 4912 \text{ nmol/L}$ or $\leq 1200 \text{ ng/mL}$
Rheumatoid factors	$\leq 1000 \text{ IU/mL}$
IgG	$\leq 70 \text{ g/L}$

Criterion: For concentrations $\leq 40 \text{ mIU/L}$ the deviation is $\leq 6 \text{ mIU/L}$. For concentrations $> 40\text{-}200 \text{ mIU/L}$ the deviation is $\leq 15 \%$. For concentrations $> 200 \text{ mIU/L}$ the deviation is $\leq 10 \%$.

There is no high-dose hook effect at PAPP-A concentrations up to 120000 mIU/L.

Pharmaceutical substances

In vitro tests were performed on 17 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

In the event that the measured PAPP-A value is conspicuously low, e.g. < 0.2 Multiple of Median (MoM), it is recommended to either exclude PAPP-A from the 1st trimester risk calculation, or to perform a 2nd trimester trisomy screening.

For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.

Limits and ranges

Measuring range

8-9300 mIU/L (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as $< 8 \text{ mIU/L}$. Values above the measuring range are reported as $> 9300 \text{ mIU/L}$ (or up to 93000 mIU/L for 10-fold diluted samples).

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 4 mIU/L

Limit of Detection = 8 mIU/L

Limit of Quantitation = 20 mIU/L

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of ≤ 20 %.

Dilution

Samples with PAPP-A concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:10 (either automatically by the analyzer or manually). The concentration of the diluted sample must be ≥ 500 mIU/L.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzer, the software automatically takes the dilution into account when calculating the sample concentration.

Expected values and clinical performance

The following results were obtained with the Elecsys PAPP-A assay:

1. *Reference range study using a panel of samples from 250 healthy non-pregnant female donors (Roche study No. R04P026)*

< 7.24 mIU/L (97.5th percentile)

2. *Performance evaluation study of the Elecsys PAPP-A assay and the Elecsys free β hCG assay in first trimester trisomy 21 risk assessment (Roche study No. B05P020 and Roche study No. CIM 000950)¹⁸*

Measurements with the Elecsys free β hCG assay and the Elecsys PAPP-A assay were conducted in 6 clinical centers in Belgium, Switzerland, Denmark, England and Germany. For the first trimester 4745 PAPP-A values were available (gestational weeks 8+0 to 13+6). Median values were calculated for each day of the respective gestational age. The table below shows the number of values available for each week and the median for the middle day of the respective week (week $n+3$). Gestational age was calculated from ultrasound crown-to-rump length (CRL) according to Robinson.¹⁹

Gestational week	8+0 to 8+6	9+0 to 9+6	10+0 to 10+6	11+0 to 11+6	12+0 to 12+6	13+0 to 13+6
Number of samples	178	302	465	805	1557	1438
Median value at the middle of the week (mIU/L)	289	580	1144	1647	2664	4349

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

For prenatal testing it is recommended that the median values be re-evaluated periodically.

Clinical performance data

In total, 2629 samples from clinical routine with known outcome were examined. 107 out of the 2629 samples were from pregnancies with confirmed Down syndrome. All samples were measured in parallel with FMF (Fetal Medicine Foundation) certified PAPP-A and free β hCG tests. Risk calculation was performed using a commercial software. This software makes use of an algorithm described by Palomaki et al.²⁰ by means of the mathematical calculations for Gaussian multivariate distribution as already published.²¹ Risk analysis is based on maternal age, nuchal translucency as well as on the results of the biochemical parameters, corrected by different factors like e.g. maternal weight, smoking and ethnic background of the pregnant woman.

Individual risk calculation

The calculation of a woman's individual risk of carrying a single fetus affected by trisomy 21 was assessed without consideration of nuchal translucency (NT) data to demonstrate the performance of the biochemical methods. Maternal weight and smoking behavior were taken into account as correction factors. Concordance of risk analysis compared to a competitor method combination was examined using the cutoff value already established in the participating laboratory.^{22,23}

It is the responsibility of the user to choose the cutoff which will apply for further procedures.

Concordance analysis data

A. Concordance analysis in unaffected pregnancies ($n = 2522$)

Cutoff 5 % FPR ^{b)}	Risk > cutoff (Roche*)	Risk < cutoff (Roche*)
Risk > cutoff (competitor**)	109 (4.32 %)	18 (0.71 %)
Risk < cutoff (competitor**)	17 (0.67 %)	2378 (94.3 %)

b) FPR = false positive rate

In 2522 unaffected samples the Roche methods correctly classified 2396 samples (specificity: 95.0 %) in comparison to 2395 (specificity: 95.0 %) correctly classified by the competitor methods.

B. Detection rate in confirmed trisomy 21 pregnancies ($n = 107$)

Cutoff 5 % FPR	Risk > cutoff (Roche*)	Risk < cutoff (Roche*)
Risk > cutoff (competitor**)	86 (80.4 %)	0
Risk < cutoff (competitor**)	4 (3.74 %)	17 (15.9 %)

In 107 affected samples the Roche methods showed a detection rate of 84.1 % (90/107) in comparison to 80.4 % (86/107) obtained with the competitor methods.

* Combination of results from the Elecsys PAPP-A assay and the Elecsys free β hCG assay

** Combination of results from the competitor's PAPP-A and free β hCG methods

Specific performance data

Representative performance data on the analyzer is given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days ($n = 84$). The following results were obtained:

cobas e 801 analyzer					
Sample	Mean mIU/L	Repeatability		Intermediate precision	
		SD mIU/L	CV %	SD mIU/L	CV %
Human serum 1	8.35	0.419	5.0	0.575	6.9
Human serum 2	18.4	0.491	2.7	0.740	4.0
Human serum 3	335	5.60	1.7	6.80	2.0
Human serum 4	2518	40.6	1.6	57.1	2.3
Human serum 5	4968	86.9	1.7	127	2.6
Human serum 6	9090	217	2.4	289	3.2
PC ^{c)} Maternal Care1	4861	63.7	1.3	89.6	1.8
PC Maternal Care2	2555	34.4	1.3	40.6	1.6
PC Maternal Care3	259	3.32	1.3	4.27	1.6

c) PC = PreciControl

Method comparison

A comparison of the Elecsys PAPP-A assay, [REF] 07027621190 (cobas e 801 analyzer; y) with the Elecsys PAPP-A assay, [REF] 04854098200 (cobas e 601 analyzer; x) gave the following correlations (mIU/mL):

Number of samples measured: 128

Passing/Bablok²⁴

Linear regression

$$y = 1.00x - 1.54$$

$$y = 1.01x - 12.8$$

$$r = 0.978$$

$$r = 0.998$$

The sample concentrations were between 7.99 and 9231 mIU/mL.

Analytical specificity

No cross-reactivity against angiotensinogen detectable.

References

- 1 Bischof P. Pregnancy-Associated Plasma Protein-A. Seminars in Reproductive Endocrinology 1992;10(2):127-135.
- 2 Rosen SW. New Placental Proteins: Chemistry, Physiology and Clinical Use. Placenta 1986;7:575-594.
- 3 Overgaard MT, Sorensen ES, Stachowiak D, et al. Complex of Pregnancy-associated Plasma Protein-A and the Proform of Eosinophil Major Basic Protein. J Biol Chem 2003;278(4):2106-2117.
- 4 Canick JA, Lambert-Messerlian GM, Palomaki GE, et al. Comparison of Serum Markers in First-Trimester Down Syndrome Screening. Obstetrics & Gynecology 2006;108(5):1192-1199.
- 5 Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31(1):7-15.
- 6 Spencer K, Crossley JA, Aitken DA, et al. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002;39:567-576.
- 7 Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7(11).
- 8 Malone FD, Canick JA, Ball RH, et al. First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome. New Eng J Med 2005;353(19):2001-2011.
- 9 Nicolaides KH, Spencer K, Avgidou K, et al. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005;25:221-226.
- 10 Cicero S, Bindra R, Rembouskos G, et al. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free β -hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn 2003;23:306-310.
- 11 Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-624.
- 12 Ghaffari SR, Tahmasebpour AR, Jamal A, et al. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β -hCG and PAPP-A: a 5-years prospective study. Ultrasound Obstet Gynecol 2012;39:528-534.
- 13 Nicolaides KH, Syngelaki A, Poon LC, et al. First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing. Fetal Diagn Ther 2014;35:185-192.
- 14 Russo ML, Blakemore KJ. A historical and practical review of first trimester aneuploidy screening. Semin Fetal Neonatal Med 2014;19(3):183-187.
- 15 Evans MI, Sonek JD, Hallahan TW, et al. Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies. Ultrasound Obstet Gynecol 2015;45:74-83.
- 16 Wright D, Wright A, Nicolaides KH. A unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol 2015;45:48-54.
- 17 ACOG Practice Bulletin No. 77. Obstet Gynecol 2007;109:217-227.
- 18 Tørring N, Aulesa C, Eiben B, et al. Performance characteristics of Elecsys free β hCG and PAPP-A for first trimester trisomy 21 risk assessment in gestational weeks 8+0 to 14+0. LaboratoriumsMedizin 2016;40(1):21-29.
- 19 Robinson HP, Fleming JE. A critical evaluation of sonar "crown-rump length" measurements. Br J Obstet Gynaecol 1975;82(9):702-710.

- 20 Palomaki GE, Haddow JE. Maternal serum α -fetoprotein, age, and Down syndrome risk. Am J Obstet Gynecol 1987;156:460-463.
- 21 Reynolds TM, Penney MD. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem 1989;27:452-458.
- 22 Bray I, Wright DE, Davies C, et al. Joint estimation of Down syndrome risk and ascertainment rates: A meta-analysis of nine published data sets. Prenat Diagn 1998;18:9-20.
- 23 Benn PA. Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing. Clin Chim Acta 2002;323:1-16.
- 24 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2019, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

